Loading
The 'moderate-severe' stage — where progression accelerates, anemia and bone disease begin, and dialysis planning conversations start.
Evidence reviewed & updated: 2026-07 — based on KDIGO 2024, KDOQI, and published trial data.
Stage 3B (eGFR 30-44) is a clinical inflection point: anemia appears in 25-40% of patients, phosphorus and PTH rise, and progression accelerates (untreated decline ~4-6 mL/min/year). This is when specialists intensify therapy, diet matters more, and 'renal replacement education' conversations begin — early planning improves outcomes significantly.
At eGFR <45, the kidney's endocrine functions fail: erythropoietin production drops (anemia), 1-α-hydroxylase activity falls (vitamin D activation ↓ → PTH ↑), and phosphorus clearance worsens (FGF-23 rises early). These are the 'CKD complications' that drive fatigue, bone disease, and cardiovascular risk.
Anemia at this stage: check hemoglobin annually (or sooner with symptoms). If Hb <10, evaluate iron (ferritin, TSAT) and consider ESA initiation per KDOQI. Treating anemia improves energy, quality of life, and outcomes.
Progression risk: eGFR decline typically accelerates below 45. The eGFR slope at this stage is the best predictor of when dialysis will be needed — knowing it enables planning instead of crisis.
All stage 3A interventions continue, plus: (1) anemia management per protocol, (2) vitamin D and CKD-MBD monitoring (calcium, phosphorus, PTH yearly, vitamin D repletion if deficient), (3) referral to a nephrologist if not yet established (mandatory at this stage in most guidelines), (4) medication review for nephrotoxic agents and dose adjustments (many drugs need renal dosing below eGFR 45).
Potassium becomes a real concern: ACEi/ARB + SGLT2i + dietary intake can push K+ up. Monitor K+ at least twice yearly; consider potassium binders (patiromer, SZC) to KEEP protective medications rather than stopping them (KDIGO 2022 approach).
Vaccination completion: hepatitis B series should be COMPLETED now — response rates fall as CKD progresses. Also: influenza (annual), pneumococcal, and COVID-19 boosters per national schedule.
Guidelines recommend modality education at stage 4-5, but evidence (CHOICE study, patient-reported data) shows that EARLY education at stage 3B-4 improves: vascular access planning (AVF before dialysis), modality choice (PD vs HD), and shared decision-making quality.
Key planning steps at stage 3B: (1) discuss prognosis honestly (estimated timeline based on eGFR slope), (2) introduce modality options (in-center HD, home HD, PD, transplant), (3) begin transplant evaluation discussion (living donor, evaluation workup), (4) arrange vascular access referral when eGFR approaches 20-25.
AVF planning: the 'Fistula First' principle — AVF creation takes 2-4 months to mature. Early referral avoids the 60-70% catheter start rate common in India (catheters carry 3-10x the infection risk).
Advertisement
Severe CKD — symptoms intensify, preparation for dialysis/transplant becomes urgent, and every decision matters.
Learn moreDiabetes is the #1 cause of kidney failure in India — here's how to protect your kidneys with SGLT2 inhibitors, BP control, and smart monitoring.
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.